Abstract:Purpose: To compare the intraindividual differences of dynamic signal characteristics for 3 gadolinium chelates (gadopentetate dimeglumine [Gd-DTPA], gadodiamide [Gd-DTPA-BMA], and gadobenate dimeglumine [Gd-BOPTA]) using dynamic contrast enhanced magnetic resonance (MR) imaging (DCE-MRI) with a preclinical beagle model at 7 Tesla.Method and Materials: Seven beagles were scanned 3 times each with a 7-day interval between the scans on a 7T whole body MRI system (Achieva, Philips) using a T/R head coil. Three different Gd contrast agents including Gd-DTPA, Gd-DTPABMA, and Gd-BOPTA were injected in a randomized order with a power injector (Spectris, MedRad, Indianola, PA) using dose of 0.1 mmol/kg body weight and flow rate of 0.06 mL/s. During image acquisition and data analysis, the identity of the specific contrast agent used for each examination was blinded. A 3D RF-spoiled fast field echo sequence was used for dynamic scans with in-plane spatial resolution 0.47 x 0.47 mm2, temporal resolution of 9.5 seconds, and a total of 60 time points. Regions of interest were drawn within the carotid arteries and muscle tissue to determine semiquantitative parameters including maximum enhancement ratio, area under the signal enhancement curve over 90 seconds after contrast injection (AUC_90), time to maximum signal enhancement (T-max), and washout_score. Additionally, quantitative pharmacokinetic parameters were measured in muscle tissues by applying 3 separate 2-compartment models; (1) artery input function (AIF) based Tofts model, (2) Brix model without AIF, and (3) AIF decomposed refined Brix model.Results: Gd-BOPTA produced higher signal to noise ratio on postcontrast T1-weighted images than the other 2 Gd based contrast agents at 7T. Quantitatively, Gd-BOPTA provided a significantly higher maximum enhancement ratio (P < 0.01), AUC_90 (P < 0.01) and washout_score (P < 0.01) in beagle musculature and cranial vasculature compared with both Gd-DTPA and Gd-DTPA-BMA. Among all the quantitative pharmacokinetic parameters, only the exchange rate constants (kep) calculated from these 3 models did not show a significant difference among the various contrast agents.Conclusions: Gd chelate containing MR contrast agents can be used at 7T for DCEMRI. Gd-BOPTA demonstrates stronger signal enhancement than standard Gd chelates, in concordance with the results of studies at lower fields. The observed enhancement characteristics for the 3 contrast agents demonstrate that the pharmacokinetic parameter kep is more robust in various models using DCE-MRI than the other pharmacokinetic parameters. This information is important relative to multisite clinical trials and long-term clinical studies that often use several different contrast agents and different models.

[Influence of Different Contrast Agent Concentrations and Injection Protocols on Dynamic Contrast Enhanced MRI of Prostate: Equimolar Comparison of 1.0M Gadobutrol and 0.5M Gadolinium Chelates]

The scanning effect of the injection flow rate of contrast medium on magnetic resonance image dynamic contrast-enhanced of prostate cancer

Gadobutrol Precedes Gd-DTPA in Abdominal Contrast-Enhanced MRA and MRI: A Prospective, Multicenter, Intraindividual Study.

Improved Display of Abdominal Contrast-Enhanced MRA Using Gadobutrol: Comparison with Gd-DTPA.

[Effects of Dynamic Contrast Enhancement on Diffusion Weighted Imaging Score of 3 in Prostate Imaging Reporting and Data System Version 2 of Peripheral Zone].

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection

Intra-Individual Comparison of Different Gadolinium-Based Contrast Agents in the Quantitative Evaluation of C6 Glioma with Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Influence of Different Contrast Agents on Dynamic Contrast-Enhanced MRI Ktrans in Cerebral Metastases: Comparison between 1.0 M Gadobutrol and 0.5M Gadopentetate Dimeglumine

Effect Of Intravenous Gadolinium-Dtpa On Diffusion-Weighted Imaging For Prostate Lesions And Normal Tissue At 3.0-Tesla Magnetic Resonance Imaging

Intraindividual In Vivo Comparison Of Gadolinium Contrast Agents For Pharmacokinetic Analysis Using Dynamic Contrast Enhanced Magnetic Resonance Imaging

Comparative Study of Using Gd-EOB-DTPA and Gd-DTPA As MR Contrast Agent for Hepatic Parenchyma and Vessles Enhacement in the Same Patient with Cirrhosis

The value of 3.0T DCE-MRI in the diagnosis of prostate cancer

Correlation between dynamic contrast-enhanced MRI and diffusion-weighted imaging of prostate cancer

Efficacy And Safety Of Gadobutrol (1.0 M) Versus Gadopentetate Dimeglumine (0.5 M) For Enhanced Mri Of Cns Lesions: A Phase Iii, Multicenter, Single-Blind, Randomized Study In Chinese Patients

Accuracy of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: Systematic Review and Meta-Analysis

Contrast-enhanced MRI of carotid atherosclerosis: Dependence on contrast agent

Prospective Study Comparing Two Iodine Concentrations for Multidetector Computed Tomography of the Pancreas

[Comparison of the Efficacy of Gadobutrol and Multihance in Contrast-Enhanced MRI for Diagnosis of Brain Metastasis in Lung Cancer].

Comparison of contrast-enhanced ultrasonography with dynamic contrast material-enhanced magnetic resonance imaging for prostate cancer detection

Relating Dose of Contrast Media Administered to Uptake and Washout of Malignant Lesions on DCEMRI of the Breast

Comparison of Early Contrast Enhancement Models in Ultrafast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Prostate Cancer